Esther Natalie O.
- Country
- Italy
- Department
- UOC Ematologia
Research Overview
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Evaluation of Eltrombopag in the Management of Thrombocytopenia in Patients with Low- and Intermediate-Risk Myelodysplastic Syndromes
Data & Insights
Has run more than one trial at 2 of 54 partner sites.
Specializations
Hematologic Disorders
This investigator specializes in treating myelodysplastic syndromes (MDS), with particular expertise in managing associated blood cell disorders. Their research encompasses therapeutic approaches for thrombocytopenia in low and intermediate-risk MDS patients.
- Blood Platelet Disorders
- Bone Marrow Function
- Hematologic Response Assessment
Specialized MDS Treatment
The investigator focuses on treating specific genetic subtypes of MDS, particularly MDS with del5q chromosomal abnormality. Their work includes developing treatments for patients with very low to intermediate risk categories according to the IPSS-R classification system.
- Genetic MDS Variants
- Risk-Stratified Treatment
- Novel Therapeutic Approaches
Transfusion Management
The investigator has developed expertise in managing transfusion-dependent anemia in MDS patients. Their work includes evaluating treatments for patients who are refractory or intolerant to conventional therapies, focusing on reducing transfusion dependency.
- Transfusion Independence
- Treatment-Resistant Anemia
- Long-term Blood Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.